BiologicalDrug
Anti-LILRB2 Monoclonal Antibody IO-108 clinical trials
Also written IO-108.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Immune-Onc Therapeutics (2) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
Atezolizumab (1) · Bevacizumab (1) · Tiragolumab (1) · Tocilizumab (1) · Amezalpat (1) · Tobemstomig (1) · Muzastotug (1) · Imdatifan (1)
Studies
Open first, then newest update. How each study uses Anti-LILRB2 Monoclonal Antibody IO-108 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingPhase 1/2Hoffmann-La RocheNCT04524871Written as IO-108 1800 mg
- First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid TumorsCompletedPhase 1Immune-Onc TherapeuticsNCT05054348Written as IO-108
- Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid TumorsCompletedPhase 1Immune-Onc TherapeuticsNCT05508100Written as IO-108